{
  "id": "c35443f8c9da2b6c",
  "title": "Key GI Cancer Advances from the 2026 ASCO Symposium",
  "description": "Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.",
  "content": "Advertisement\n\nx\n\nAdvertisement\n\nNews\\|Articles\\|January 30, 2026\n\n# Key GI Cancer Advances from the 2026 ASCO Symposium\n\nAuthor(s) [_Ryan Scott_](https://www.curetoday.com/authors/ryan-scott)\n\nFact checked by: [_Spencer Feldman_](https://www.curetoday.com/authors/spencer-feldman)\n\nListen\n\n0:00 / NaN:NaN\n\n### Key Takeaways\n\n- The BREAKWATER trial demonstrated the efficacy of a BRAF-targeted regimen using FOLFIRI, offering a neuropathy-free option for metastatic colorectal cancer patients.\n\n- HERIZON-GEA-01 trial results showed improved survival with Ziihera and immunotherapy in HER2-amplified gastric cancer, indicating a significant advancement.\n\n- Emerging data suggested GLP-1 agonists might offer preventive benefits against colorectal cancer, potentially expanding their use in younger populations.\n\nSHOW MORE\n\nDr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.\n\nAdvertisement\n\n![Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.](https://cdn.sanity.io/images/0vv8moc6/curetoday/f79d371a58dfb14eb09e3da3c4f9aece449df388-1200x1200.jpg?w=1200&max-h=1200&fit=crop&auto=format)\n\n_Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium._\n\n![](https://cdn.sanity.io/images/0vv8moc6/curetoday/f79d371a58dfb14eb09e3da3c4f9aece449df388-1200x1200.jpg?fit=crop&auto=format)\n\nThis years [**2026 ASCO Gastrointestinal Cancers Symposium**](https://www.curetoday.com/conference/asco-gastrointestinal-cancers-symposium) was packed with practice-shaping data across colorectal and upper gastrointestinal malignancies, according to Dr. Suneel Kamath, who sat down for an interview with CURE following the meeting.\n\nDuring the conversation, Kamath highlighted advances in biomarker-driven therapies, emerging frontline regi",
  "source": "curetoday.com",
  "source_url": "https://www.curetoday.com/view/key-gi-cancer-advances-from-the-2026-asco-symposium",
  "published_at": "20260131T011500Z",
  "fetched_at": "2026-02-01T00:32:37.375926+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.curetoday.com/view/key-gi-cancer-advances-from-the-2026-asco-symposium",
    "url_mobile": "",
    "title": "Key GI Cancer Advances from the 2026 ASCO Symposium",
    "seendate": "20260131T011500Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/curetoday/855364b9d0be64e5a6941b0246d325f594adf567-1280x720.jpg",
    "domain": "curetoday.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}